Company profile

InduPro, Inc.

Privately held: no public share price (Launched 2024 with an $85M Series A; privately held, no listing. [resolved 2026-08-05 by resolve-null-is-public; source: https://www.prnewswire.com/news-releases/indupro-announces-85-million-series-a-financing-appoints-prakash-raman-phd-as-ceo-to-advance-next-generation-proximity-based-protein-therapeutics-for-the-treatment-of-cancer-and-autoimmune-diseases-302171386.html]) · United States

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
IDP-001
Phase 2
EGFR (domain III) and CDCP1 (bispecific)Small molecule
Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.